Suppr超能文献

加巴喷丁剂量增加对神经性疼痛疗效更佳:灵活剂量临床试验的深入分析

Neuropathic pain responds better to increased doses of pregabalin: an in-depth analysis of flexible-dose clinical trials.

作者信息

Serpell Michael, Latymer Mark, Almas Mary, Ortiz Marie, Parsons Bruce, Prieto Rita

机构信息

University Department of Anaesthesia, Stobhill Ambulatory Care Hospital, Glasgow.

Pfizer Ltd, Tadworth, UK.

出版信息

J Pain Res. 2017 Jul 26;10:1769-1776. doi: 10.2147/JPR.S129832. eCollection 2017.

Abstract

BACKGROUND

Pregabalin is an effective treatment option for many patients with neuropathic pain. Higher doses of pregabalin have been shown to be more effective in improving pain outcomes but, in practice, failing to appropriately increase the dose can leave patients under-treated.

METHODS

This was a pooled analysis of 6 flexible-dose clinical trials of pregabalin in patients with neuropathic pain (diabetic peripheral neuropathy, peripheral herpetic neuralgia, posttraumatic pain, or postsurgical pain). Patients were divided into "dose pathway" groups based on their weekly pregabalin dose from the start of their trial to the first week of their maintenance phase. These were: 150 mg/day only; 150 to 300 mg/day; 150 to 300 to 450 mg/day; 150 to 300 to 450 to 600 mg/day; 150 to 300 to 600 mg/day; 300 to 600 mg/day. Pain outcomes assessed for each group at each new dose were proportion of 30% and 50% responders (≥30% or ≥50% reduction in mean pain score from baseline) and mean change in pain score. Percent change in mean pain score from baseline was assessed using a marginal structural model.

RESULTS

Seven hundred and sixty-one patients treated with flexible-dose pregabalin were included in the analysis. For each dose pathway group, there was a notably greater proportion of 30% and 50% responders and change in pain score, at each escalating dose. As assessed by the marginal structural model, higher doses of pregabalin were estimated to result in a significantly greater change in mean pain score at each week. This dose response with flexible-dose pregabalin was consistent with that previously observed with fixed-dose pregabalin.

CONCLUSION

Many patients who do not respond to lower doses of pregabalin will respond with notable improvements in pain outcomes when the dose is escalated. These data should encourage physicians treating patients with neuropathic pain to escalate pregabalin to the dose that delivers optimal analgesia and tolerable side effects.

摘要

背景

普瑞巴林是许多神经性疼痛患者的有效治疗选择。已表明较高剂量的普瑞巴林在改善疼痛结局方面更有效,但在实际应用中,未能适当增加剂量可能导致患者治疗不足。

方法

这是一项对6项普瑞巴林治疗神经性疼痛患者(糖尿病性周围神经病、周围性疱疹后神经痛、创伤后疼痛或术后疼痛)的灵活剂量临床试验的汇总分析。根据患者从试验开始到维持期第一周的每周普瑞巴林剂量,将患者分为“剂量路径”组。这些组分别为:仅150毫克/天;150至300毫克/天;150至300至450毫克/天;150至300至450至600毫克/天;150至300至600毫克/天;300至600毫克/天。在每个新剂量下为每组评估的疼痛结局是30%和50%缓解者的比例(平均疼痛评分较基线降低≥30%或≥50%)以及疼痛评分的平均变化。使用边际结构模型评估平均疼痛评分相对于基线的百分比变化。

结果

分析纳入了761例接受灵活剂量普瑞巴林治疗的患者。对于每个剂量路径组,在每次剂量递增时,30%和50%缓解者的比例以及疼痛评分变化都明显更高。根据边际结构模型评估,估计较高剂量的普瑞巴林在每周都会导致平均疼痛评分有显著更大的变化。这种灵活剂量普瑞巴林的剂量反应与先前观察到的固定剂量普瑞巴林的剂量反应一致。

结论

许多对较低剂量普瑞巴林无反应的患者在剂量增加时疼痛结局会有显著改善。这些数据应鼓励治疗神经性疼痛患者的医生将普瑞巴林剂量增加至能提供最佳镇痛效果且副作用可耐受的剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/186d/5536312/93754c91d016/jpr-10-1769Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验